Drugs / Nexvax2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02528799 | Aug 2015 → Jan 2017 | celiac disease | ImmusanT, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00879749 | Apr 2009 → Mar 2010 | celiac disease | Nexpep Pty Ltd | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03644069 | Aug 2018 → Sep 2019 | celiac disease | ImmusanT, Inc. | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nexvax2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00879749 ↗ |
| Action | Restore | “ultimately restore tolerance to gluten in patients with celiac disease.” PMID 29191561 ↗ Nov 2017 |
| Modality | Peptide | “Nexvax2® is a novel, peptide-based, epitope-specific immunotherapy” PMID 29191561 ↗ Nov 2017 |
| Route | Other | “Nexvax2 intra-dermal injections twice weekly” NCT02528799 ↗ |